Freya Biosciences Has $38m And A Plan To Change Women’s Lives
Executive Summary
Emerging Company Profile: Armed with a new tranche of funding, the Danish group is aiming to improve the lot of infertile couples by altering the microbiome of patients with dysbiosis.
You may also be interested in...
IPOs Fizzle Out In The Fourth Quarter
Just three biotech companies floated in the last three months of 2023, but there may be hope for a resurgence next year.
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.